Gavreto - direct healthcare professional communication (DHPC)

pralsetinib
DHPCHuman

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Gavreto
Active substance
pralsetinib
Therapeutic area (MeSH)
Carcinoma, Non-Small-Cell Lung
Procedure number
EMEA/H/C/005413
Regulatory outcome
Variation
DHPC type
  • Adverse event
  • Post-authorisation measure
Human ATC codes
L01XE
Dissemination date

Share this page